Details of the Drug Reposition | DrugMAP

General Information of This Drug (ID: DMSWNJF)

Drug Name	Ravulizumab DMSWNJF
Synonyms	Ravulizumab [USAN]; UNII-C3VX249T6L; C3VX249T6L; ALXN1210
Drug Type	Antibody

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)

1 Approved Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Paroxysmal nocturnal haemoglobinuria	DISBHMYH	3A21.0	Approved	[1]
------------------------------------------------------------------------------------

1 Phase 3 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Coronavirus Disease 2019 (COVID-19)	DISM7GNX	1D6Y	Phase 3	[2]
------------------------------------------------------------------------------------

References

1	FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (BLA) 761108.
2	ClinicalTrials.gov (NCT04369469) Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia. U.S. National Institutes of Health.